Impact of delay between imaging and treatment in patients with potentially curable pancreatic cancer

British Journal of Surgery

Volumn 103, Issue 3, 2016, Pages 267-275

  Sanjeevi, S ^a   Ivanics, T ^c   Lundell, L ^b   Kartalis, N ^b   Andren Sandberg A ^b   Blomberg, J ^b   Del Chiaro, M ^b   Ansorge, C ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; CARCINOMA, PANCREATIC DUCTAL; DIAGNOSTIC IMAGING; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; LAPAROTOMY; MALE; MIDDLE AGED; PANCREAS RESECTION; PANCREATIC NEOPLASMS; PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDY; TIME FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LAPAROTOMY; MALE; MIDDLE AGED; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84955377662     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.10046     Document Type: Article

References (30)

1. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014; 74: 2913-2921.
2. Erkan M., The role of pancreatic stellate cells in pancreatic cancer. Pancreatology 2013; 13: 106-109.
3. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al., Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467: 1114-1117.
4. Kleeff J, Michalski C, Friess H, Buchler MW. Pancreatic cancer: from bench to 5-year survival. Pancreas 2006; 33: 111-118.
5. Li Q, Yan H, Liu W, Zhen H, Yang Y, Cao B. Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trials. PloS One 2014; 9: e104346.
6. Witkowski ER, Smith JK, Tseng JF. Outcomes following resection of pancreatic cancer. J Surg Oncol 2013; 107: 97-103.
7. Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB III, Casper ES,; National Comprehensive Cancer Network. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 2012; 10: 703-713.
8. Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J Gastrointest Oncol 2012; 3: 105-119.
9. Allen VB, Gurusamy KS, Takwoingi Y, Kalia A, Davidson BR. Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer. Cochrane Database Syst Rev 2013; (11)CD009323.
10. Raman SP, Reddy S, Weiss MJ, Manos LL, Cameron JL, Zheng L, et al., Impact of the time interval between MDCT imaging and surgery on the accuracy of identifying metastatic disease in patients with pancreatic cancer. AJR Am J Roentgenol 2015; 204: W37-W42.
11. Gurusamy K, Davidson BR. Diagnostic accuracy of different imaging modalities following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer. Cochrane Database Syst Rev 2015; (2)CD011515.
12. Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 2009; 16: 1727-1733.
13. Yamada S, Fujii T, Sugimoto H, Nomoto S, Takeda S, Kodera Y, et al., Aggressive surgery for borderline resectable pancreatic cancer: evaluation of National Comprehensive Cancer Network guidelines. Pancreas 2013; 42: 1004-1010.
14. Park H, An S, Eo SH, Song KB, Park JH, Kim KP, et al., Survival effect of tumor size and extrapancreatic extension in surgically resected pancreatic cancer: proposal for improved T classification. Hum Pathol 2014; 45: 2341-2346.
15. Adsay NV, Bagci P, Tajiri T, Oliva I, Ohike N, Balci S, et al., Pathologic staging of pancreatic, ampullary, biliary, and gallbladder cancers: pitfalls and practical limitations of the current AJCC/UICC TNM staging system and opportunities for improvement. Semin Diagn Pathol 2012; 29: 127-141.
16. Barugola G, Partelli S, Marcucci S, Sartori N, Capelli P, Bassi C, et al., Resectable pancreatic cancer: who really benefits from resection? Ann Surg Oncol 2009; 16: 3316-3322.
17. Yu J, Blackford AL, Dal Molin M, Wolfgang CL, Goggins M. Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages. Gut 2015; 64: 1783-1789.
18. Glant JA, Waters JA, House MG, Zyromski NJ, Nakeeb A, Pitt HA, et al., Does the interval from imaging to operation affect the rate of unanticipated metastasis encountered during operation for pancreatic adenocarcinoma? Surgery 2011; 150: 607-616.
19. Kneuertz PJ, Cunningham SC, Cameron JL, Torrez S, Tapazoglou N, Herman JM, et al., Palliative surgical management of patients with unresectable pancreatic adenocarcinoma: trends and lessons learned from a large, single institution experience. J Gastrointest Surg 2011; 15: 1917-1927.
20. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al., New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
21. Loizou L, Albiin N, Ansorge C, Andersson M, Segersvard R, Leidner B, et al., Computed tomography staging of pancreatic cancer: a validation study addressing interobserver agreement. Pancreatology 2013; 13: 570-575.
22. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al., The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009; 250: 187-196.
23. Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA, Michor F. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell 2012; 148: 362-375.
24. Pisters PW, Hudec WA, Hess KR, Lee JE, Vauthey JN, Lahoti S, et al., Effect of preoperative biliary decompression on pancreaticoduodenectomy-associated morbidity in 300 consecutive patients. Ann Surg 2001; 234: 47-55.
25. van der Gaag NA, Rauws EA, van Eijck CH, Bruno MJ, van der Harst E, Kubben FJ, et al., Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med 2010; 362: 129-137.
26. Arkadopoulos N, Kyriazi MA, Papanikolaou IS, Vasiliou P, Theodoraki K, Lappas C, et al., Preoperative biliary drainage of severely jaundiced patients increases morbidity of pancreaticoduodenectomy: results of a case-control study. World J Surg 2014; 38: 2967-2972.
27. Raman SP, Horton KM, Fishman EK. Multimodality imaging of pancreatic cancer-computed tomography, magnetic resonance imaging, and positron emission tomography. Cancer J 2012; 18: 511-522.
28. Motosugi U, Ichikawa T, Morisaka H, Sou H, Muhi A, Kimura K, et al., Detection of pancreatic carcinoma and liver metastases with gadoxetic acid-enhanced MR imaging: comparison with contrast-enhanced multi-detector row CT. Radiology 2011; 260: 446-453.
29. Zuckerman DS, Ryan DP. Adjuvant therapy for pancreatic cancer: a review. Cancer 2008; 112: 243-249.
30. Malin JL, Asch SM, Kerr EA, McGlynn EA. Evaluating the quality of cancer care: development of cancer quality indicators for a global quality assessment tool. Cancer 2000; 88: 701-707.